A detailed history of Bank Of America Corp transactions in Allakos Inc. stock. As of the latest transaction made, Bank Of America Corp holds 243,614 shares of ALLK stock, worth $214,380. This represents 0.0% of its overall portfolio holdings.

Number of Shares
243,614
Previous 307,253 20.71%
Holding current value
$214,380
Previous $307,000 48.53%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.54 - $0.92 $34,365 - $58,547
-63,639 Reduced 20.71%
243,614 $158,000
Q2 2024

Aug 14, 2024

SELL
$1.0 - $1.45 $222,363 - $322,426
-222,363 Reduced 41.99%
307,253 $307,000
Q1 2024

May 15, 2024

BUY
$1.02 - $3.23 $172,244 - $545,440
168,867 Added 46.81%
529,616 $667,000
Q4 2023

Feb 14, 2024

SELL
$1.72 - $3.18 $37,277 - $68,920
-21,673 Reduced 5.67%
360,749 $984,000
Q2 2023

Aug 14, 2023

SELL
$3.6 - $5.25 $1.86 Million - $2.72 Million
-517,498 Reduced 57.5%
382,422 $1.67 Million
Q1 2023

May 12, 2023

BUY
$4.3 - $8.27 $1.9 Million - $3.66 Million
442,798 Added 96.87%
899,920 $4 Million
Q4 2022

Feb 10, 2023

BUY
$5.66 - $8.42 $1.91 Million - $2.83 Million
336,581 Added 279.23%
457,122 $3.85 Million
Q3 2022

Nov 14, 2022

SELL
$3.02 - $6.12 $209,823 - $425,205
-69,478 Reduced 36.56%
120,541 $737,000
Q2 2022

Aug 12, 2022

BUY
$2.6 - $6.14 $351,790 - $830,766
135,304 Added 247.29%
190,019 $594,000
Q1 2022

May 16, 2022

SELL
$5.08 - $9.81 $641,258 - $1.24 Million
-126,232 Reduced 69.76%
54,715 $312,000
Q4 2021

Feb 08, 2022

BUY
$8.55 - $111.89 $1.33 Million - $17.3 Million
155,029 Added 598.15%
180,947 $1.77 Million
Q3 2021

Nov 15, 2021

BUY
$76.53 - $110.43 $179,233 - $258,627
2,342 Added 9.93%
25,918 $2.74 Million
Q2 2021

Sep 13, 2021

BUY
$85.37 - $114.1 $2.01 Million - $2.69 Million
23,576 New
23,576 $2.01 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $74.6M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.